ArticleClinical lymphoma, myeloma & leukemia2019

Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.

Bruno Emond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.